GlassScriptPhysician profile
Jonathon Tyler Reed
NPI 1609574805
$590.00
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.95 · 2024: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $133.92 | 2024 | |
| Amgen INC. | $119.85 | 2024 | Repatha |
| Philips North America LLC | $63.98 | 2024 | (Ck4) Mcot, (5044) Mcot |
| Boston Scientific Corporation | $52.36 | 2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $48.08 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $37.36 | 2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $36.05 | 2023-2024 | |
| Recor Medical INC | $24.73 | 2024 | Paradise Renal Denervation System |
| Astrazeneca Pharmaceuticals LP | $17.87 | 2024 | Wainua |
| Merck Sharp & Dohme LLC | $14.36 | 2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $13.84 | 2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $13.25 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.